Brainstorm Cell Therapeutics Soars 45%

Brainstorm Cell Therapeutics Inc BCLI surged 45 percent in Friday’s premarket, adding to the stock’s gain of 22.68 percent on Wednesday.

Interest in the stock has grown ahead of the company’s January 5 conference call to discuss clinical results from a recent trial.

"We are very excited to share the final results of this study. Professor Karussis presented a very positive and well-received interim analysis of this study at the Joint Congress of European Neurology in June 2014, and the final results include data from several additional subjects and analyses conducted by our independent statisticians,” according to a recent statement by CEO Tony Fiorino.

Brainstorm Cell Therapeutics traded recently at $6.80, up 43 percent.